Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
 to Ring the Nasdaq Stock Market Opening Bell on January 11 - EconoTimes)
New York, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Oasmia Pharmaceutical AB (Nasdaq:OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced that the Company will ring the Nasdaq Opening Bell on Monday, January 11 in honor of its recent listing on the Nasdaq Capital Market.
"On behalf of the entire Oasmia team, we are honored and appreciative of the opportunity to ring the Nasdaq Opening Bell," said Julian Aleksov, Executive Chairman of Oasmia. "We believe the human and animal oncology treatments we have brought to market, as well as the next-generation technologies we continue to develop, will have a profound impact on the treatment of various cancers for both patients and physicians. With our recently established US sales and marketing platform, we are confident in the continued adoption of our family of products, making us well-positioned for future growth and recognition among US security-holders."
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live - The ceremony will begin at approximately 9:20am EST.
The Company began trading on the Nasdaq Capital Market on October 23, 2015.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM.ST), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and Nasdaq Capital Market (OASM.US).
Julian Aleksov, Executive Chairman
Tel: +46 18 50 54 40
E-mail: [email protected]
For media relations:
Eric Fischgrund
Founder FischTank
Tel: +1 (646) 699 1414
E-mail: [email protected]
For investor relations:
Robert Haag
Managing Partner
IRTH Communications
Tel: +1 (866) 976 4784
E-mail: [email protected]
